NEW YORK, June 18, 2018 Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Catalyst Biosciences, Inc. (“Catalyst” or the “Company) (NASDAQ: CBIO). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/cbio.
The investigation concerns whether Catalyst and certain of its officers and/or directors have violated federal securities laws.
On June 18, 2018, Catalyst announced that neutralizing antibodies were detected in Cohort 6 of the Phase 1/2 trial of CB 2679d/ISU304, Catalyst’s hemophilia B treatment, and that Catalyst had halted the trial in order to “conduct an analysis to assess the cause and impact of the antibody observations prior to dosing any further subjects in Cohort 6.” Following this announcement, Catalyst’s share price fell sharply during intraday trading on June 18, 2018.
If you are aware of any facts relating to this investigation, or purchased Catalyst shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/cbio. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
SOURCE Bronstein, Gewirtz & Grossman, LLC